CorMedix (CRMD) Misses Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
CorMedix Inc. Reports Second Quarter 2016 Financial Results and Provides Business Updates
August 5, 2016 8:05 AM EDTBEDMINSTER, NJ -- (Marketwired) -- 08/05/16 -- CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases, today reported financial results for the second quarter ended June 30, 2016 and highlighted recent business updates. The Company will host a conference call today at 9:00 a.m. Eastern Time.
Key Business and Financial Updates:
Neutrolin Phase 3 LOCK-IT 100 study in hemodialysis patients: Continue to enroll patients and engage clinical sites; overall program remains on track. Anticipated... More
